drugset / Trial / NCT00381654
Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
AV-412 is a new oral therapy developed to inhibit the growth of solid tumors in patients who have not responded to standard therapy or surgical interventions, or who have experienced relapse. This study will test the safety of AV-412 and determine the maximum tolerated dose for the treatment of solid tumors.
Timeline
- Start
- 2006-10
- Primary completion
- 2009-12
- Completion
- 2010-02
Outcome
Outcome not reported
Stopped: “Study did not meet pre-specified objectives.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AV-412 | Small molecule | 25 mg | Oral |
| Subject | AV-412 | Small molecule | 50 mg | Oral |
| Subject | AV-412 | Small molecule | 100 mg | Oral |
| Subject | AV-412 | Small molecule | 200 mg | Oral |